Serum caspase-9 levels are increased in patients with amyotrophic lateral sclerosis.

It is known that apoptosis may play a role in the pathophysiology of amyotrophic lateral sclerosis (ALS). Moreover, caspase-9 is implicated in the apoptosis pathway. The aim of the study was to investigate caspase-9 levels in serum of patients with ALS. The study involved 30 patients with ALS and 30 patients from the control group. The serum caspase-9 levels were measured using the enzyme-linked immunosorbent method. The study showed that caspase-9 levels are significantly increased in serum of the patients with ALS comparing to the control group (p < 0.05). There was a significant correlation of serum caspase-9 levels with severity of clinical state of ALS patients and duration of the disease (p < 0.05). The results indicate that caspase-9 may be implicated in pathomechanism of neurodegeneration in ALS.

Introduction

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons. Apoptosis mediates programmed natural death of neurons and is a physiologically important process in neurogenesis. However, premature apoptosis and/or an aberration in apoptosis regulation may be implicated in the pathogenesis of neurodegeneration in different neurological diseases, including ALS [1]. Mitochondria play a key role in the apoptotic process. Among the two of the signaling pathways of apoptosis, i.e., the “extrinsic” and the “intrinsic” pathways, the latter is assumed to initiate in mitochondria. Its activation involves the release of cytochrome c and other pro-apoptotic factors from the mitochondrial intermembrane space. In the cytosol, cytochrome c binds to the apoptosis protease activation factor (APAf-1) and forms a complex indicated as “apoptosome.” The complex-induced activation of pro-caspase-9 initiates an enzymatic reaction cascade leading to the execution of apoptosis in cells [2]. Caspase-9 is a member of caspase family of cysteine proteases. Activated caspase-9 cleaves downstream caspases such as caspase-3, -6, and -7 initiating the caspase cascade [3].

Data from the literature showed that apoptosis may play a role in pathomechanism of ALS and degeneration of motor neurons in this disease [4, 5]. Hetz et al. [6] demonstrated that the proapoptotic Bcl-2 family member Bcl-2-interacting mediator of cell death (BIM) mediates motoneuron loss in a model of ALS. The apoptosis markers, including caspase-9, are activated in the ventral horn of motor neurons in a transgenic mouse model of ALS [7, 8]. According to Guégan et al. [9] the mitochondrial-dependent programmed cell death pathway, including the redistribution of Bax, the cytosolic release of cytochrome c, and the activation of caspase-9, is recruited during neurodegeneration in spinal cords of transgenic SOD1 mouse model of ALS. It was also observed that the G93A mutant SOD1 interaction with DNA might induce DNA damage and trigger the apoptotic response by activating p53. This toxic activity of mutant SOD1 in the nucleus may play an important role in the complex mechanisms associated with motor neuron death observed in ALS pathogenesis [10]. The extracellular nucleotides mediate neuronal apoptosis via pathways involving C-jun N-terminal kinase 1 (JNK1), extracellular signal-regulated kinase (ERK), and caspases 8/9/3 [11]. The balance between anti- and pro-apoptotic proteins related to endoplasmic reticulum (ER) stress is impaired from the pre-symptomatic stage in this ALS mouse model, and this imbalance may be related to the pathogenesis of motor neuron degeneration in ALS [12].

Inoue et al. [13] examined the effects of inhibition of X chromosome-linked inhibitor of apoptosis (XIAP), a mammalian inhibitor of caspase-3, -7, and -9. It was observed that XIAP attenuated disease progression without delaying onset. The authors suggest that caspase-9 plays a crucial role in progression of ALS and constitutes a promising therapeutic target. Thus, apoptosis contributes to pathology in ALS, and appropriate anti-apoptosis therapy might therefore be beneficial in this disease [14].

Although caspase-9 is an intracellular protein, it was suggested that serum markers of apoptosis may be noninvasive biomarkers in patients [15]. Moreover, data from the literature shows that measurement of caspases in serum could be useful in monitoring different diseases [16-19]. The aim of the study was to measure serum caspase-9 levels in patients with ALS and to investigate whether there is a relationship of this caspase with clinical parameters of the disease.

Materials and methods

Thirty ALS patients took part in the study. The ALS was diagnosed according to the El Escorial criteria of ALS [20]. There were 23 patients with clinically definite ALS (the presence of upper motor neuron as well as lower motor neuron signs in the bulbar region and at least two spinal regions, or the presence of upper motor neuron signs in two spinal regions and lower motor neuron signs in three spinal regions) and 7 patients with clinically probable ALS [upper motor neuron and lower motor neuron signs in at least two regions with some upper motor neuron signs rostral to (above) the lower motor neuron signs] according to these criteria. The clinical condition of the patients was measured by the revised version of Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS-R] [21]. According to this scale the ALS patients scored from 0 to 39 points. They were divided into two subgroups: patients with a mild clinical state (over 24 points according to ALSFRS-R) and patients with a severe clinical state (up to 24 points according to ALSFRS-R). The patients with the ALS were also divided according to the type of the disease onset (patients with a limb-onset and patients with a bulbar-onset). The average duration of ALS was 16 months (3 months–7 years). According to the duration of the disease, the two subgroups of patients were isolated (patients with a short duration of ALS ≤12 months and patients with a long duration of ALS >12 months). All patients with ALS had nutritional deficiencies. The restriction of food consumption, malnutrition, and weight loss was observed because of progressive weakening of the muscles and dysphagia.

The control group consisted of 30 patients with tension-type headache. The patients from the control group were recruited out of hospitalized patients and that is why healthy persons were not included in the study. The patients from control group were admitted to the hospital because of acute headache occurred and it was necessary to exclude subarachnoid hemorrhage. The characteristics of patients are presented in Table 1.

Table 1

Characteristics of patients

Group	No. of patients	Age (years)	Male/female
Control	30	50 ± 7	15/15
ALS: total	30	54 ± 6	17/13
ALS: short duration	16	54 ± 3	9/7
ALS: long duration	14	54 ± 8	8/6
ALS: bulbar onset	12	60 ± 7	4/8
ALS: limb onset	18	50 ± 5	13/5
ALS: mild clinical state	14	49 ± 2	9/5
ALS: severe clinical state	16	57 ± 6	8/8

The study was approved by the Ethics Committee of Medical University and performed in accordance with the ethical standards established in Helsinki.

Serum samples were collected into the plastic tubes, centrifuged rapidly, and stored at −70°C until the analysis was performed. Caspase-9 levels were measured by the enzyme-linked immunosorbent method using the commercial ELISA kit for human Caspase-9 (Bender MedSystems, Austria) in accordance with the manufacturer’s instructions. The nonparametric Mann–Whitney rank sum test was used to examine the differences between the groups because data was not normally distributed. The correlation analysis was performed using the Spearman rank correlation. The caspase-9 values are expressed in ng/mL, as median and range. P values <0.05 were considered significant.

Results

The study showed that the caspase-9 levels are significantly increased in the serum of the whole group of patients with ALS [5.4 (0.0–32.2) ng/mL] compared with those from the control group [2.65 (0.0–14.3) ng/mL] (p < 0.05). Caspase-9 levels were still significantly increased in ALS patients with long duration of the disease, with severe clinical state, and with bulbar onset of ALS compared with controls (p < 0.05) but not in ALS patients with short duration of the disease, with mild clinical state and with limb onset of ALS compared with controls (p > 0.05). The difference in the serum caspase-9 levels between subgroups of ALS patients according to the division of their type of ALS onset, severity of clinical state, and duration of the disease was not significant (p > 0.05).

The median values of the serum caspase-9 levels, and a comparative analysis between subgroups are presented in Fig. 1 and in Table 2.

Fig. 1

Serum caspase-9 level in patients with ALS and control (p = 0.03)

Table 2

Serum caspase-9 levels in patients with ALS and a comparative analysis between groups

Group	Caspase-9 level (ng/ml); median and range	Comparison
ALS: short duration	4.9 (0.0–25.4)	Control versus ALS: short duration p = 0.16
ALS: long duration	9.25 (0.0–32.2)
		Control versus ALS: long duration p = 0.03*
		ALS short versus long duration p = 0.31
ALS: bulbar onset	8.0 (0.0–23.7)	Control versus ALS: bulbar onset p = 0.04*
ALS: limb onset	4.90 (0.0–32.2)	Control versus ALS: limb onset p = 0.13
		ALS bulbar versus limb onset p = 0.59
ALS: mild clinical state	3.9 (0.0–15.7)	Control versus ALS: mild clinical state p = 0.33
ALS: severe clinical state	8.8 (0–32.2)
		Control versus ALS: severe clinical state p = 0.01*
		ALS mild versus severe clinical state p = 0.11

Data is expressed as median and range. Mann–Whitney rank sum test

* p statistically significant, at least p < 0.05

The correlation between serum caspase-9 and severity of clinical state of ALS patients (ALSFRS-R score) and duration of the disease was statistically significant (r = 0.61, p = 0.01 and r = 0.48, p = 0.03; respectively).

There was no significant difference between of the age of patients in ALS and controls (p = 0.47). There were also no significant differences between the age of male and female in patients with ALS and controls (p = 0.35 and p = 0.28; respectively).

The difference of serum caspase-9 levels between ALS male and female, and between younger (≤55 years) and older (>55 years) patients with ALS was not significant (p = 0.61 and p = 0.14; respectively).

Discussion

There is evidence that apoptosis and activation of caspase-9 play a role in different neurological diseases.

Darwish et al. [22] showed that activated caspase-9 and cytochrome c are present in the cerebrospinal fluid (CSF) of patients with severe traumatic brain injury.

Caspase-9 plays an important role in the development of multiple sclerosis (MS). It was suggested that polymorphisms in the caspase-9 gene may influence the activity of the disease [23].

According to Yu et al. [24], chronic extrinsic cervical spinal cord compression leads to Fas-mediated apoptosis of neurons and oligodendrocytes which is associated with activation of caspase-8, -9, and -3 and progressive neurological deficits.

Spinal and bulbar muscular atrophy (SBMA) is a motor neuron disease caused by polyglutamine expansion mutation in the androgen receptor (AR). Ranganathan et al. [25] showed that the mutant protein in MN-1 cells resulted in increased Bax, caspase-9, and caspase-3.

The pilocarpine-induced status epilepticus (SE) results in massive degenerative death of neuronal cells in brains. The degenerating neurons, most of them also expressing apoptosis signalling molecules such as caspase-9 and activated caspase-3 [26].

Blandini et al. [27] measured the activity of proapoptotic caspase-3 and -9 in peripheral blood lymphocytes (PBLs) of Parkinson Disease (PD) and Alzheimer Disease (AD) patients. Marked increases in caspase-3 and -9 activity were found.

Presenilin 1 (PS1) gene mutations are the major causes of early onset familial AD. Acceleration of apoptosis, elevation of caspase-3/7 activity, and significant increases in caspase-4, -8, and -9 activities during apoptosis induced by several agents were found in the mutant PS1-transfected cells [28].

It has been postulated that the pathogenesis of PD is associated with mitochondrial dysfunction. Rotenone caused the loss of mitochondrial membrane potential, released cytochrome c into the cytosol, reduced cytochrome c content in mitochondria, and reduced activation of caspase-9 and -3 [29].

It was suggested that molecular targeting of the Apaf-1-caspase-9 signalling pathway may be a feasible neuroprotective strategy to enhance the endogenous threshold for caspase activation and prevent neuronal loss in stroke [30]. It was showed that acetaminophen reduces apoptosis (and activation of caspase-9) in an in vivo model of cerebral ischemia–reperfusion [31].

It was demonstrated that agents that improve mitochondrial function or inhibit the permeability transition may eliminate increased caspase -3 and -9 activation and cell death associated with enhanced N-methyl-d-aspartate receptor (NMDAR) activity in Huntington’s disease (HD) [32].

It is known that sera from 26% of patients with sporadic ALS induced in vitro apoptosis of a human neuroblastoma cell line. In mixed cultures of rat embryonic brain and spinal cord cells the sera from ALS patients induced the apoptosis of a subpopulation of motoneurons [33]. It was demonstrated that intrathecally infused TAT-fused protein was effectively transferred into spinal cord neurons of ALS transgenic mice, including motor neurons, and that intrathecal infusion of TAT-modified Bcl-X(L) delayed disease onset, prolonged survival, and improved motor performance. Histological studies show the attenuation of motor neuron loss and decrease in the number of cleaved caspase 9-, cleaved caspase 3-, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)-positive cells in the lumbar cords of TAT-modified Bcl-X(L)-treated G93A mice [34].

This study showed that the caspase-9 levels are significantly increased in the serum of the whole group of patients with ALS compared with those from the control group. This indicates that caspase-9 is implicated in pathophysiology of ALS. It may be interesting to know caspase-9 levels also in the cerebrospinal fluid of patients with ALS but this measurement will be the subject of the next research. Caspase-9 levels were significantly increased in ALS patients with long duration of the disease, with severe clinical state, and with bulbar onset of ALS compared with controls but not in ALS patients with short duration of the disease, with mild clinical state, and with limb onset of ALS compared with controls. The correlation between serum caspase-9 and severity of clinical state of ALS patients, and the duration of the disease was statistically significant. This indicates that apoptosis is more advanced in patients with severe clinical state, bulbar onset, and a long duration of the disease. Moreover, it is known that patients with bulbar onset of ALS have more severe clinical state than patients with limb onset of the disease. Tokuda et al. [35] demonstrated that caspases are present in nonactive forms in the spinal cords of wild-type mice during the early stage of the disease. In transgenic mice, the caspases are present in their active forms. During the advanced stage of the disease, when paralysis is present, the active caspases levels are increased. Data from the recent study confirm this observation and suggest that caspase-9 plays a role in pathophysiology of ALS, and anti-apoptotic therapy might be helpful in this disease.